# Rosiglitazone-Metformin Combination Versus Metformin-Sulfonylurea Combination On Beta-Cell Function In Type 2 Diabetes

> **NCT00367055** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 84 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** rosiglitazone-metformin
- **DRUG:** Metformin
- **DRUG:** metformin+ gliclazide

## Key facts

- **NCT ID:** NCT00367055
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2010-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00367055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00367055, "Rosiglitazone-Metformin Combination Versus Metformin-Sulfonylurea Combination On Beta-Cell Function In Type 2 Diabetes". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT00367055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*